Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Solu Therapeutics, Inc
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06950034CT.gov A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Monocytic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Stx-0712 (this asset) | Solu Therapeutics, Inc | P1 | CC · 43 |
| Etoposide | Stanford University | P3 | BBB |
| Cytarabine | Chinese PLA General Hospital | P3 | BBB |
| Daunomycin | National Cancer Institute (NCI) | P3 | BBB |
| Nivestim | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | P3 | BBB |
| Cyclophosphamide | ECOG-ACRIN Cancer Research Group | P3 | BBB |
| 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- | National Cancer Institute (NCI) | P2 | BBB |
| Mitoxantrone | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | P2/3 | BBB |
| Idarubicin | Chinese PLA General Hospital | P3 | BBB |
+41 more in the Acute Monocytic Leukemia cohort
Other indications for Stx-0712
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Therapy Related Acute Myeloid Leukemia And Myelodysplastic Syndrome | — | P1 | CC · 41 |
| Chronic Myelomonocytic Leukemia | — | P1 | C · 39 |
| Acute Myeloid Leukemia | — | P1 | C · 36 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Stx-0712 in Acute Monocytic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/stx-0712-acute-monocytic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →